Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.
Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. 52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Horwitz, S. M., Kim, Y. H., Foss, F. M., Zain, J. M., Myskowski, P., Lechowicz, M. J., Fisher, D. C., Shustov, A., Bartlett, N. L., Delioukina, M. L., Koutsoukos, T., Fruchtman, S. M., O'Connor, O. A., Duvic, M. AMER SOC HEMATOLOGY. 2010: 1154–55View details for Web of Science ID 000289662203132